Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in Platinum-Refractory Ovarian Cancer
NCT00016224Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2001
- Primary completion
- Mar 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in ovarian epithelial carcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Time to Progression. Started Jan 2001; status: completed.
02
Drugs
thalidomide
03
Conditions
ovarian epithelial carcinoma
Beyond the preview
Go deeper on NCT00016224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016224.